FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FibroGen (NASDAQ: FGEN) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. CEO Thane Wettig will present on Tuesday, September 10 at 3:00 PM ET at the Lotte New York Palace Hotel. The presentation will be livestreamed and later available for replay on FibroGen's website for 90 days.
The company's management team will be available for one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to schedule meetings. This event provides an opportunity for FibroGen to showcase its developments and engage with potential investors.
FibroGen (NASDAQ: FGEN) ha annunciato la sua partecipazione alla 26a Conferenza Annuale di Investimenti Globale H.C. Wainwright che si svolgerà dal 9 all'11 settembre 2024 a New York. Il CEO Thane Wettig presenterà martedì 10 settembre alle 15:00 ET presso il Lotte New York Palace Hotel. La presentazione sarà trasmessa in diretta e successivamente disponibile per la visione on-demand sul sito web di FibroGen per 90 giorni.
Il team di gestione dell'azienda sarà disponibile per incontri individuali durante la conferenza. Gli investitori interessati dovrebbero contattare il loro rappresentante H.C. Wainwright per programmare gli incontri. Questo evento offre a FibroGen l'opportunità di mettere in mostra i propri sviluppi e interagire con potenziali investitori.
FibroGen (NASDAQ: FGEN) anunció su participación en la 26ª Conferencia Anual de Inversión Global H.C. Wainwright, que se llevará a cabo del 9 al 11 de septiembre de 2024 en Nueva York. El CEO Thane Wettig presentará el martes 10 de septiembre a las 15:00 ET en el Lotte New York Palace Hotel. La presentación será transmitida en vivo y estará disponible posteriormente para su reproducción en la página web de FibroGen durante 90 días.
El equipo de gestión de la empresa estará disponible para reuniones uno a uno durante la conferencia. Los inversores interesados deben contactar a su representante de H.C. Wainwright para programar reuniones. Este evento ofrece a FibroGen la oportunidad de mostrar sus avances e interactuar con potenciales inversores.
FibroGen (NASDAQ: FGEN)는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. CEO Thane Wettig가 9월 10일 화요일 오후 3시(ET) Lotte New York Palace Hotel에서 발표할 예정입니다. 해당 발표는 라이브 스트리밍되며, 이후 90일 동안 FibroGen의 웹사이트에서 다시 시청할 수 있습니다.
회사의 관리 팀은 컨퍼런스 기간 동안 일대일 회의를 위해 참석할 것입니다. 관심 있는 투자자는 H.C. Wainwright의 담당자에게 연락하여 회의를 일정 잡아야 합니다. 이 행사는 FibroGen이 개발 현황을 선보이고 잠재적 투자자와의 관계를 맺을 수 있는 기회를 제공합니다.
FibroGen (NASDAQ: FGEN) a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright, qui se tiendra du 9 au 11 septembre 2024 à New York. Le PDG Thane Wettig présentera le mardi 10 septembre à 15h00 ET au Lotte New York Palace Hotel. La présentation sera diffusée en direct et disponible ultérieurement en replay sur le site de FibroGen pendant 90 jours.
L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles durant la conférence. Les investisseurs intéressés doivent contacter leur représentant H.C. Wainwright pour programmer des réunions. Cet événement offre à FibroGen l'opportunité de mettre en avant ses développements et d'échanger avec des investisseurs potentiels.
FibroGen (NASDAQ: FGEN) gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt, die vom 9. bis 11. September 2024 in New York stattfindet. CEO Thane Wettig wird am Dienstag, den 10. September um 15:00 Uhr ET im Lotte New York Palace Hotel präsentieren. Die Präsentation wird live übertragen und anschließend für 90 Tage auf der Website von FibroGen verfügbar sein.
Das Management-Team des Unternehmens steht während der Konferenz für persönliche Gespräche zur Verfügung. Interessierte Investoren sollten ihren H.C. Wainwright-Vertreter kontaktieren, um Meetings zu vereinbaren. Diese Veranstaltung bietet FibroGen die Gelegenheit, seine Entwicklungen zu präsentieren und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
SAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 10 at 3:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here.
FibroGen’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, when available, to the FibroGen website on the Events & Presentation page of the investors section for 90 days.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
ir@fibrogen.com
FAQ
When is FibroGen (FGEN) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for FibroGen (FGEN) at the H.C. Wainwright conference?
Where can I watch FibroGen's (FGEN) presentation at the H.C. Wainwright conference?
Can investors meet with FibroGen's (FGEN) management team during the H.C. Wainwright conference?
